Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers

被引:30
作者
Kakuda, T. N. [1 ]
Scholler-Gyure, M. [2 ]
De Smedt, G. [2 ]
Beets, G. [2 ]
Aharchi, F. [2 ]
Peeters, M. P. [2 ]
Vandermeulen, K. [2 ]
Woodfall, B. J. [2 ]
Hoetelmans, R. M. W. [2 ]
机构
[1] Tibotec Inc, Yardley, PA 19067 USA
[2] Tibotec BVBA, Mechelen, Belgium
关键词
drug-drug interaction; etravirine; HIV; tenofovir disoproxil fumarate; PLACEBO-CONTROLLED TRIAL; EXPERIENCED HIV-1-INFECTED PATIENTS; HIV-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE; DOUBLE-BLIND; ATAZANAVIR-RITONAVIR; ANTIRETROVIRAL-NAIVE; TMC125; ETRAVIRINE; RESISTANT HIV-1; IN-VITRO;
D O I
10.1111/j.1468-1293.2008.00668.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Two open-label, randomized, cross-over trials in healthy volunteers were conducted to investigate the pharmacokinetic interaction between etravirine and tenofovir disoproxil fumarate. Etravirine was administered as either 800 mg twice a day (bid) (phase II formulation in Study 1) or 200 mg bid (phase III formulation in Study 2) for 8 days followed by a 12 h pharmacokinetic evaluation. After a minimum of 14 days washout, tenofovir disoproxil fumarate 300 mg once a day was administered for 16 days. Volunteers were randomized to receive co-administration of etravirine with tenofovir disoproxil fumarate on either days 1-8 or days 9-16 followed by a 12 h pharmacokinetic evaluation for etravirine on day 8 or 16, respectively. Plasma and urine tenofovir concentrations were determined on days 8 and 16 over 24 h. The least square mean (LSM) ratio [90% confidence interval (CI)] for the area under the plasma concentration-time curve from 0 to 12 h (AUC(12 h)) for etravirine co-administered with tenofovir disoproxil fumarate vs. etravirine alone was 0.69 (0.61-0.79) and 0.81 (0.75-0.88) in Studies 1 and 2, respectively. The LSM ratio (90% CI) for the effect of etravirine on tenofovir AUC(24 h) was 1.16 (1.09-1.23) in Study 1 and 1.15 (1.09-1.21) in Study 2. These alterations are not considered clinically relevant for either drug and no dose adjustment is necessary when etravirine and tenofovir disoproxil fumarate are co-administered.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 45 条
[1]  
AGARWALA S, 2005, 6 INT WORKSH CLIN PH
[2]   TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].
Andries, K ;
Azijn, H ;
Thielemans, T ;
Ludovici, D ;
Kukla, M ;
Heeres, J ;
Janssen, P ;
De Corte, B ;
Vingerhoets, J ;
Pauwels, R ;
de Béthune, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686
[3]   Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis [J].
Arribas, Jose R. ;
Pozniak, Anton L. ;
Gallant, Joel E. ;
DeJesus, Edwin ;
Gazzard, Brian ;
Campo, Rafael E. ;
Chen, Shan-Shan ;
McColl, Damian ;
Holmes, Charles B. ;
Enejosa, Jeffrey ;
Toole, John J. ;
Cheng, Andrew K. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) :74-78
[4]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[5]   The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients [J].
Cassetti, Isabel ;
Madruga, Jose Valdez R. ;
Suleiman, Jamal Muhamad A. H. ;
Etzel, Arnaldo ;
Zhong, Lijie ;
Cheng, Andrew K. ;
Enejosa, Jeffrey .
HIV CLINICAL TRIALS, 2007, 8 (03) :164-172
[6]   Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state [J].
Chittick, GE ;
Zong, J ;
Blum, MR ;
Sorbel, JJ ;
Begley, JA ;
Adda, N ;
Kearney, BP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1304-1310
[7]  
COHEN C, 2006, 16 INT AIDS C TOR
[8]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[9]   From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125):: Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase [J].
De Corte, BL .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1689-1696
[10]   Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: The TENOPLUS study [J].
Dominguez, Stephanie ;
Ghosn, Jade ;
Peytavin, Gilles ;
Izzedine, Hassan ;
Wirden, Marc ;
Ktorza, Nadine ;
Miller, Michael ;
Aubron-Olivier, Camille ;
Trylesinski, Aldo ;
Calvez, Vincent ;
Deray, Gilbert ;
Katlama, Christine .
JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (02) :105-110